Cargando…
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
BACKGROUND: Fingolimod is used for immune therapy in patients with multiple sclerosis. Long-term treatment is associated with a small increase in the risk of herpes virus reactivation and respiratory tract infections. Patients with coronavirus disease 2019 (COVID-19) under Fingolimod treatment have...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202802/ https://www.ncbi.nlm.nih.gov/pubmed/32408155 http://dx.doi.org/10.1016/j.msard.2020.102180 |
_version_ | 1783529763871129600 |
---|---|
author | Foerch, Christian Friedauer, Lucie Bauer, Boris Wolf, Timo Adam, Elisabeth H. |
author_facet | Foerch, Christian Friedauer, Lucie Bauer, Boris Wolf, Timo Adam, Elisabeth H. |
author_sort | Foerch, Christian |
collection | PubMed |
description | BACKGROUND: Fingolimod is used for immune therapy in patients with multiple sclerosis. Long-term treatment is associated with a small increase in the risk of herpes virus reactivation and respiratory tract infections. Patients with coronavirus disease 2019 (COVID-19) under Fingolimod treatment have not been described. METHODS AND RESULTS: We report a 57-year old female patient with a relapsing remitting multiple sclerosis under fingolimod treatment who experienced a severe COVID-19 infection in March 2020 (Extended Disability Status Scale: 2.0). Having peripheral lymphopenia typical for fingolimod treatment (total lymphocytes 0.39/nL [reference range 1.22-3.56]), the patient developed bilateral interstitial pneumonia with multiple ground-glass opacities on chest CT. Fingolimod medication was stopped. On the intensive care unit, non-invasive ventilation was used to provide oxygen and ventilation support regularly. Over the following two days, oxygenation improved, and the patient was transferred to a normal ward five days after admission. CONCLUSION: The implications fingolimod has on COVID-19 are complex. As an S1P analogue, fingolimod might enhance lung endothelial cell integrity. In addition, in case of a so-called cytokine storm, immunomodulation might be beneficial to reduce mortality. Future studies are needed to explore the risks and therapeutic effects of fingolimod in COVID-19 patients. |
format | Online Article Text |
id | pubmed-7202802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Author(s). Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72028022020-05-07 Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod Foerch, Christian Friedauer, Lucie Bauer, Boris Wolf, Timo Adam, Elisabeth H. Mult Scler Relat Disord Case Report BACKGROUND: Fingolimod is used for immune therapy in patients with multiple sclerosis. Long-term treatment is associated with a small increase in the risk of herpes virus reactivation and respiratory tract infections. Patients with coronavirus disease 2019 (COVID-19) under Fingolimod treatment have not been described. METHODS AND RESULTS: We report a 57-year old female patient with a relapsing remitting multiple sclerosis under fingolimod treatment who experienced a severe COVID-19 infection in March 2020 (Extended Disability Status Scale: 2.0). Having peripheral lymphopenia typical for fingolimod treatment (total lymphocytes 0.39/nL [reference range 1.22-3.56]), the patient developed bilateral interstitial pneumonia with multiple ground-glass opacities on chest CT. Fingolimod medication was stopped. On the intensive care unit, non-invasive ventilation was used to provide oxygen and ventilation support regularly. Over the following two days, oxygenation improved, and the patient was transferred to a normal ward five days after admission. CONCLUSION: The implications fingolimod has on COVID-19 are complex. As an S1P analogue, fingolimod might enhance lung endothelial cell integrity. In addition, in case of a so-called cytokine storm, immunomodulation might be beneficial to reduce mortality. Future studies are needed to explore the risks and therapeutic effects of fingolimod in COVID-19 patients. The Author(s). Published by Elsevier B.V. 2020-07 2020-05-06 /pmc/articles/PMC7202802/ /pubmed/32408155 http://dx.doi.org/10.1016/j.msard.2020.102180 Text en © 2020 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Case Report Foerch, Christian Friedauer, Lucie Bauer, Boris Wolf, Timo Adam, Elisabeth H. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |
title | Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |
title_full | Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |
title_fullStr | Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |
title_full_unstemmed | Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |
title_short | Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |
title_sort | severe covid-19 infection in a patient with multiple sclerosis treated with fingolimod |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202802/ https://www.ncbi.nlm.nih.gov/pubmed/32408155 http://dx.doi.org/10.1016/j.msard.2020.102180 |
work_keys_str_mv | AT foerchchristian severecovid19infectioninapatientwithmultiplesclerosistreatedwithfingolimod AT friedauerlucie severecovid19infectioninapatientwithmultiplesclerosistreatedwithfingolimod AT bauerboris severecovid19infectioninapatientwithmultiplesclerosistreatedwithfingolimod AT wolftimo severecovid19infectioninapatientwithmultiplesclerosistreatedwithfingolimod AT adamelisabethh severecovid19infectioninapatientwithmultiplesclerosistreatedwithfingolimod |